New precision medicine opportunities in advanced prostate cancer: from molecular understanding to treatment targeting
Growing preclinical and clinical evidence supports the combination of PARP (Poly (ADP-ribose) polymerase) inhibition with new generation anti-hormonal agents (NHA) and/or radioligand therapy, especially, but not exclusively, in patients carrying alteration in DNA-repairs’ pathways.
| Organiser | ESU (European School of Urology) |
|---|---|
| CME | To be approved |
| Duration | Approx. 60 minutes |
Understanding the different proliferation pathways that prostate cancer (PCa) cells may promote at advanced stages of the disease is the key factor for the identification of biomarkers for patients’ molecular classification and treatment selection strategy.
In this e-course, insights regarding the relevant cellular mechanisms will be presented, as well as which biomarkers might help in identifying the most appropriate treatment; also, an overview of latest evidence of radioligands in PCa theranostics will be provided.